AUTHORS
Xiaoli Liang, Xiaoqi Wang, MD, PhD2, Hongfei Hu3, Luying Wang, PhD4, Li Li5, Jia Liu6, Min Zhao7, Zhihan Liu8, Yiru Ma9, Lianghui Mao10, Hongchao Li, PhD11, Xi Zhang, MD12
AFFILIATIONS
1 Xinqiao Hospital of Army Medical University, Chongqing, China, Xinqiao Hospital of Army Medical University, Chongqing, China
2 Xinqiao Hospital of Army Medical University, Chongqing, China, Xinqiao Hospital of Army Medical University, Chongqing, China
3 China Pharmaceutical University, Nanjing, China, China Pharmaceutical University, Nanjing, China
4 China Pharmaceutical University, Nanjing, China, China Pharmaceutical University, Nanjing, China
5 Xinqiao Hospital of Army Medical University, Chongqing, China, Xinqiao Hospital of Army Medical University, Chongqing, China
6 Xinqiao Hospital of Army Medical University, Chongqing, China, Xinqiao Hospital of Army Medical University, Chongqing, China
7 China Pharmaceutical University, Nanjing, China, China Pharmaceutical University, Nanjing, China
8 China Pharmaceutical University, Nanjing, China, China Pharmaceutical University, Nanjing, China
9 China Pharmaceutical University, Nanjing, China, China Pharmaceutical University, Nanjing, China
10 China Pharmaceutical University, Nanjing, China, China Pharmaceutical University, Nanjing, China
11 China Pharmaceutical University, Nanjing, China, China Pharmaceutical University, Nanjing, China
12 Xinqiao Hospital of Army Medical University, Chongqing, China, Xinqiao Hospital of Army Medical University, Chongqing, China
ABSTRACT
Objective
Chronic graft-versus-host disease (cGVHD) is a prolonged, multisystem complication of allogeneic hematopoietic stem cell transplantation. Routine care typically focuses on organ involvement, disease severity, and treatment response. However, patients must also manage complex treatments, healthcare access, financial burden, and disruption of daily and social roles. These concerns may influence treatment continuity and everyday functioning, but are not routinely captured by organ-focused assessment. This study aimed to identify patient-reported challenges relevant to long-term cGVHD management and to characterize needs that extend beyond organ symptoms.
Methods
In a cross-sectional mixed-methods study, 61 adults with active cGVHD were purposively recruited from two hospitals in Chongqing and Hangzhou, China. Participants completed a questionnaire that covered sociodemographic data and the Modified 7-Day Lee cGVHD Symptom Scale (LSS), and underwent semi-structured interviews addressing symptom characteristics, treatment experience, healthcare utilization, functional impact, and psychosocial burden. Interviews were audio-recorded, transcribed verbatim, and analyzed through iterative qualitative coding and constant comparison. This study was approved by the Xinqiao Hospital of Army Medical University ethnic committee (approval NO.2025-Research No. 395-02)
Results
Participants had a mean age of 40.8 years; 55.7% were male, mean cGVHD duration was 20.2 months, and 59.0% had moderate-to-severe disease. The mean LSS score was 18.4 (SD 11.3), with dry eyes, shortness of breath with exercise, and need to use eye drops frequently being the most frequently reported symptom. Meanwhile, six interrelated management-relevant challenges emerged from the qualitative findings. First, fluctuating multisystem symptoms required continuous monitoring and daily self-management, including medication use, dietary modifications, infection precautions, oxygen use, and activity adjustments. Second, patients balanced treatment benefits against associated burdens, including long-term polypharmacy, adverse effects from corticosteroids and other treatments, concerns about medication dependence, the time and effort required to adhere to medications, and the absence of a clear treatment endpoint. Third, healthcare delivery imposed additional burdens. Patients described travel for care, frequent hospital visits, complex appointment and testing procedures, long waiting times with limited consultation time, and insufficient communication regarding their concerns or medications. Fourth, financial pressure directly altered treatment and healthcare decisions. Patients reported that reimbursement restrictions affected medication selection, and some delayed care, were unable to maintain medication adherence, attempted to reduce treatment, or considered abandoning treatment because of cost. Fifth, physical and functional impairment interfered with employment, education, self-care, family responsibilities, and social participation, limiting independence and return to normal life. Sixth, patients reported anxiety, uncertainty, loneliness, stigma, perceived burden on family members, and insufficient emotional or social support. These challenges were mutually reinforcing. Functional limitations reduced the ability to work, while ongoing medical expenses heightened financial pressure. Barriers to care, limited information, and insufficient support further intensified uncertainty and distress, complicating self-management and treatment adherence. Overall, the interviews identified needs spanning symptom self-management, treatment support, access to care, financial, functional, and psychosocial support.
Conclusion
The burden of managing cGVHD extends beyond organ symptoms. Patients need simultaneously manage multisystem manifestations, prolonged treatment, healthcare utilization, financial constraints, and family and social roles. Organ involvement and disease-severity assessments alone may not identify the issues that threaten treatment continuity or the patient’s ability to maintain a normal life. Patient-centered cGVHD management should systematically assess treatment burden, access barriers, financial pressure, functional limitations, and psychosocial needs alongside disease activity and organ involvement.
DISCLOSURES
Hongfei Hu: No relevant conflicts of interest to declare.